In-Depth Study on Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape.
Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.
Complete report available @ Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 25, 27, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 1 and 1 molecules, respectively.
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology)
- The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4SC AG AbbVie Inc Actinium Pharmaceuticals Inc ADC Therapeutics Sarl Affimed GmbH Alfa Wassermann SpA Alissa Pharma Amgen Inc Arno Therapeutics Inc Bristol-Myers Squibb Company Celgene Corp Cell Medica Ltd Cellectis SA Celleron Therapeutics Ltd Cellular Biomedicine Group Inc Constellation Pharmaceuticals Inc Cornerstone Pharmaceuticals Inc Curis Inc Faron Pharmaceuticals Oy Incyte Corp Kite Pharma Inc MedImmune LLC Merck & Co Inc Merck KGaA Mesoblast Ltd Millennium Pharmaceuticals Inc Mirati Therapeutics Inc Molecular Templates Inc NantKwest Inc NBE-Therapeutics AG Pfizer Inc Philogen SpA Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rich Pharmaceuticals Inc Seattle Genetics Inc Selvita SA Spectrum Pharmaceuticals Inc Stemline Therapeutics Inc Syndax Pharmaceuticals Inc Taiwan Liposome Company Ltd Theravectys SA TRACON Pharmaceuticals Inc Trillium Therapeutics Inc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
posted by Reportstack @ 04:16
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home